Your partner in Europe
  • Print page
  • Bookmark Page


Recordati offers both prescription and OTC products in a wide range of therapeutic areas.

Recordati’s flagship product is ZANIDIP® (lercanidipine), a latest generation calcium-channel blocker for the treatment of hypertension. It is a lipophilic dihydropyridine, discovered and entirely developed by Recordati, with the following characteristics: natural once a day, potent, long-lasting vasodilatory activity, highly vasoselective with gradual onset, smooth and uniform blood pressure lowering activity and improved tolerability over other dihydropyridines.


Our Markets

Last updated on:
03:22:37 CET
Delivered by Investis (opens in a new window)